Welch & Forbes LLC Has $6.69 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Welch & Forbes LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 105,497 shares of the biopharmaceutical company’s stock after selling 5,466 shares during the quarter. Welch & Forbes LLC’s holdings in Gilead Sciences were worth $6,686,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in GILD. Nuveen Asset Management LLC increased its stake in Gilead Sciences by 1,208.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 9,847,359 shares of the biopharmaceutical company’s stock valued at $665,288,000 after buying an additional 9,094,586 shares during the period. Renaissance Technologies LLC increased its stake in shares of Gilead Sciences by 56.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock worth $860,731,000 after purchasing an additional 4,620,000 shares during the last quarter. Invesco Ltd. increased its stake in shares of Gilead Sciences by 17.5% during the 2nd quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock worth $1,552,213,000 after purchasing an additional 3,418,193 shares during the last quarter. Marshall Wace North America L.P. increased its stake in shares of Gilead Sciences by 298.3% during the 2nd quarter. Marshall Wace North America L.P. now owns 3,418,196 shares of the biopharmaceutical company’s stock worth $230,934,000 after purchasing an additional 2,559,972 shares during the last quarter. Finally, Miller Howard Investments Inc. NY acquired a new position in shares of Gilead Sciences during the 2nd quarter worth $93,386,000. Hedge funds and other institutional investors own 79.57% of the company’s stock.

NASDAQ GILD opened at $63.99 on Friday. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. The company has a fifty day simple moving average of $64.11 and a 200 day simple moving average of $65.34. The company has a market cap of $81.04 billion, a P/E ratio of 10.40, a P/E/G ratio of 2.94 and a beta of 1.10. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $76.44.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.14. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. Gilead Sciences’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.91 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 6.66 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.94%. The ex-dividend date of this dividend was Thursday, September 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In related news, EVP Brett A. Pletcher sold 7,200 shares of the company’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,716 shares of company stock valued at $821,299. 0.20% of the stock is owned by insiders.

Several research analysts have recently commented on GILD shares. Jefferies Financial Group set a $95.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, July 15th. BMO Capital Markets set a $82.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Maxim Group set a $84.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Monday, July 15th. Finally, Raymond James set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Friday, August 23rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $82.24.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: How are institutional investors different from individual investors?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.